Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases

Marie Pierik1, Sofie Joossens, Kristel Van Steen

  • 1Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium. Marieke.Pierik@uz.kuleuven.ac.be

Inflammatory Bowel Diseases
|December 24, 2005
PubMed

Insights

Genetic variants in Toll-like receptor (TLR) genes 1, 2, and 6 are associated with inflammatory bowel disease (IBD) phenotypes, particularly extensive colitis in ulcerative colitis and Crohn's disease. These findings highlight the role of innate immunity in IBD pathogenesis.

Area of Science:

  • Immunogenetics
  • Gastroenterology
  • Molecular Biology

Background:

  • Growing evidence suggests a deficient innate immune response to gut bacteria contributes to inflammatory bowel disease (IBD) pathogenesis.
  • Previous associations include CARD15 variants with Crohn's disease (CD) and Toll-like receptor (TLR) 4 polymorphisms with IBD.
  • This study investigated nonsynonymous polymorphisms in other TLR genes in IBD patients.

Purpose of the Study:

  • To investigate the association between nonsynonymous polymorphisms in Toll-like receptor (TLR) genes 1-10 and inflammatory bowel disease (IBD).
  • To determine if specific TLR variants influence the disease phenotype in patients with IBD.

Main Methods:

  • Identified 35 single nucleotide polymorphisms (SNPs) in TLR1-10 from public databases.
  • Genotyped 284 IBD parent-child trios and 285 IBD patients with 191 healthy controls using polymerase chain reaction-restriction fragment length polymorphisms.
  • Performed genotype-phenotype analyses on pooled patient data.

Main Results:

  • No SNPs were associated with overall IBD susceptibility.
  • TLR1 R80T and TLR2 R753G SNPs were positively associated with pancolitis in ulcerative colitis (UC).
  • TLR6 S249P showed a negative association with proctitis-only UC, and TLR1 S602I was negatively associated with ileal disease in CD.

Conclusions:

  • Nonsynonymous variants in TLR1, TLR2, and TLR6 genes are associated with extensive colonic disease in UC and CD.
  • These findings underscore the involvement of TLRs and their cofactors in the innate immune response to bacteria.
  • The study highlights the critical role of an abnormal innate immune response in the pathogenesis of IBD.
Abstract

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...